Table 1. ATG gene dysregulation in Vastus lateralis muscles from pre-symptomatic and symptomatic OPMD patients.
| OPMD 60.2 ± 6.6 years Female % 66.6 | Pre-symptomatic 38.5 ± 1.5 years Female % 8.3 | |||
|---|---|---|---|---|
| Gene | p-value | Fold change | p-value | Fold change |
| ATG12 | 0.00 | -0.36 | 0.67 | -0.06 |
| ULK1 | 0.01 | -0.51 | 0.27 | -0.24 |
| ATG16L2 | 0.01 | -0.04 | 0.10 | -0.04 |
| GABARAPL2 | 0.02 | -0.20 | 0.86 | 0.02 |
| IFNA16 | 0.03 | -0.03 | 0.83 | 0.01 |
| ATG9A | 0.03 | -0.20 | 0.34 | -0.10 |
| ATG4A | 0.04 | -0.12 | 0.16 | 0.08 |
| WIPI2 | 0.04 | -0.02 | 0.84 | 0.01 |
| ATG10 | 0.05 | -0.18 | 0.97 | 0.00 |
| IFNAR2 | 0.01 | 0.15 | 0.27 | 0.07 |
| ATG4D | 0.04 | 0.14 | 0.81 | -0.02 |
| BECN1 | 0.05 | 0.07 | 0.45 | -0.09 |
P-values and fold changes (log2) were calculated from age-matched control groups using the hierarchical linear model [13], p<0.01 was set as a threshold in OPMD. For the same genes, p-value and fold change are also shown in pre-symptomatic. Per group average age ± standard deviation and % of females are indicated.